BarrettHChildsMD

Oncology • Riverdale, NY

Physician

Join to view full profile

Dr. Childs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Childs' full profile

Already have an account?

Office
5410 Netherland Avenue
Riverdale, NY 10471
Phone+1 917-214-7887

Fax+1 862-404-4303

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1982 - 1985
Rutgers Robert Wood Johnson Medical SchoolClass of 1982, MD

Certifications & Licensure

NY State Medical License 1983 - 2026
FL State Medical License 1993 - 2005
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

91 citations
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid...
Raffit Hassan, George R. Blumenschein, Kathleen N. Moore, Alessandro D. Santin, Hedy L. Kindler
Journal of Clinical Oncology. 2020-03-26
25 citations
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts
The Lancet. Oncology. 2022-04-01
367 citations
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation : Effect of patient age and donor leukocyte infusions
Trudy N. Small, Esperanza B. Papadopoulos, Farid Boulad, P Black, Hugo Castro-Malaspina
Blood. 1999-01-15

Lectures

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long-Term Efficacy and Safety from the Copanlisib CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018